Kornimate/medical-research-clean huggingface dataset:
comparison of dexlansoprazole mr to placebo on the ability to maintain healing in subjects with healed erosive esophagitis

Conditions: Esophagitis, Reflux; Esophagitis, Peptic

Summary: the purpose of this study is to assess the ability of once-daily (qd) treatment with dexlansoprazole modified-release (mr) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (ee).

this is a phase 3, randomized, double-blind, multi-center, placebo-controlled, 6 month maintenance study. the study is designed to compare the efficacy and safety of daily dexlansoprazole mr (60 mg and 90 mg) with that of placebo, in maintaining healing of erosive esophagitis. because the development plan for dexlansoprazole mr formulation was revised, the results of 2 identical studies, t-ee04-086 (nct00255164) and t-ee04-087 (this study, nct00255151), were combined and analyzed as a single larger study referred to as study t-ee04-086. a total of 451 subjects were included in the combined analysis: 237 subjects were enrolled into study t-ee04-086, and 214 subjects were enrolled into study t-ee04-087.

Eligibility criteria:
inclusion criteria: * subjects must have successfully completed the phase 3 study t-ee04-084 (nct00251693) or t-ee04-085 (nct00251719); and have healed esophageal erosions proven by endoscopy. complete healing was assessed for change in la esophagitis classification grades a, b, c, or d to healed (defined as anything less than the criterion for grade a). the subject was counted as healed if endoscopy findings did not meet the grade a criterion. exclusion criteria: * use of prescription or nonprescription proton pump inhibitors (ppis), histamine (h2) receptor antagonists, sucralfate, misoprostol, or prokinetics throughout the study * use of antacids (except for study supplied) throughout the study. * subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose throughout the study. * need for continuous anticoagulant therapy.

Keywords: erosive esophagitis
rapid-rf: remote active monitoring in patients with heart failure

Conditions: Heart Failure

Summary: the rapid-rf registry aims to characterize latitude® patient management's alert feature: latitude active monitoring™ by evaluating type and frequency of alert notifications and alert-related medical interventions. this registry will also assess clinical outcomes including quality of life and new york heart association class changes over time, mortality, hospitalizations and heart failure-related event rates.


Eligibility criteria:
inclusion criteria: * patients who meet current indications for a guidant rf-enabled crt-d device (e.g. contak renewal 3 rf family of crt-d devices) which is compatible with the latitude communicator. indications include: nyha class iii, iv; ef of ≤ 35%; qrs duration of ≥ 120 ms; and optimized pharmacologic therapy * patients who have an analog telephone line compatible with the latitude communicator. the latitude communicator must be placed within 8 feet of where they sleep for successful remote interrogations to occur. * patients who receive the study components including the latitude communicator, weight scale, and blood pressure monitor * patients who are willing and capable of providing informed consent prior to implant and willing to participate in the rapid-rf registry * patients who remain in the clinical care of a rapid-rf investigator at approved centers exclusion criteria: * patients who are expected to receive a heart transplant during the course of the study * patients who have received or who will receive a tricuspid valve prosthesis during the course of the study * patients who have previously received an implantable cardiac resynchronization device (e.g., biventricular pacemaker or biventricular icd) * patients whose life expectancy is less than 12 months * patients who are currently enrolled in another observational registry or investigational study that could directly impact the treatment or outcome of the rapid-rf registry. contact guidant's clinical application research study (cars) department to determine eligibility. * patients who are younger than 18 years of age * patients who are pregnant or plan to become pregnant during the study * patients who are unable or refuse to comply with the protocol requirements

Keywords: heart failure remote monitoring implantable device
xarelto [spaf-qol] post-marketing surveillance in japan

Conditions: Non-valvular Atrial Fibrillation (NVAF)

Summary: the objective of this study is to understand if rivaroxaban can improve treatment satisfaction of warfarin patients and assess the safety and effectiveness of xarelto in real clinical practice. a total of 725 patients are to be enrolled and followed for a 6 months.period. qol survey will be conducted at month 0, 3, 6 using acts/tsqm. this study is categorized as a regulatory post-marketing surveillance in japan, and it is a local prospective and observational study of patients who have received xarelto for spaf.


Eligibility criteria:
inclusion criteria: * patients treated by warfarin for their atrial fibrillation for at least two months at the time of the study initiation. * rivaroxaban naïve patients * patients 20 years old or older. * patients who agree to sign the inform consent exclusion criteria: * patients who are contraindicated by product label

Keywords: xarelto spaf qol
s.p.pro liver powder is used to improve liver and metabolic indexes in people with non-alcoholic fatty liver disease

Conditions: Liver Diseases

Summary: with the westernization of the diet and insufficient exercise, taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty liver disease has gradually increased. although weight loss, dietary adjustments, and certain drug treatments can delay the deterioration of the disease; however, weight loss and dietary adjustment are not easy.

with the westernization of the diet and insufficient exercise, taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty liver disease has gradually increased. although weight loss, dietary adjustments, and certain drug treatments can delay the deterioration of the disease; however, weight loss and dietary adjustment are not easy. moreover, drugs also have side effects, and there is currently no convenient and effective treatment for people who have non-alcoholic fatty liver disease. the purpose of this trial is that investigating and evaluating the effects on fatty liver, liver fiber, and metabolic indexes after subjects using shen pu yang gan wan.

Eligibility criteria:
inclusion criteria: * patients with fatty liver diagnosed by abdominal ultrasound or hepatic fibrometer within half a year's data * subjects with the non-alcoholic fatty liver disease * the severity of fatty liver should be at least 3 points by taking an abdominal ultrasound exclusion criteria: * female patients are pregnant or breastfeeding. * patients with viral hepatitis. * long-term drinkers. * those who use slimming products and vitamin e.
a clinical study of kdt-3594 in japanese patients with early parkinson's disease

Conditions: Parkinson Disease

Summary: objective of this study is to investigate the safety, pharmacokinetics and efficacy of kdt-3594 in patients with early parkinson's disease without a concomitant medication of l-dopa.


Eligibility criteria:
inclusion criteria: * japanese patients * patients who are diagnosed with parkinson's disease according to uk parkinson's disease society brain bank clinical diagnostic criteria * patients with parkinson's disease in stages 1 to 3 on the modified hoehn and yahr scale exclusion criteria: * patients who are suspected any parkinsonism except for idiopathic parkinson's disease. * patients who underwent neurosurgical treatment (stereotaxic destruction, deep brain stimulation etc.) for pd, or patients for whom surgical treatment is scheduled during the study * patients with a complication of obvious dementia, or patients with mini-mental state examination (mmse) score \< 24 points
the value of measuring retinal vascular density by optical coherence tomography-angiography (oct-a) in patients with microvascular angina confirmed by myocardial microcirculatory resistance index (mri).

Conditions: Microvascular Angina

Summary: microvascular angina is thought to affect around 112 million patients worldwide. however, this figure is underestimated due to the difficulty of making the diagnosis. it is a pathology caused by an alteration in the microcirculation of the heart muscle, which is not detectable on a standard coronary angiogram. in view of its prognostic, therapeutic and medico-economic value, scientific societies currently recommend invasive measurement of the microcirculatory resistance index (mri) to diagnose microvascular angina, in the absence of significant lesions on coronary angiography. several research teams, including our own, have shown that cardiovascular risk is associated with alterations in the vascularization of the small vessels (microcirculation) of the retina. unlike the study of cardiac vessels, the study of retinal microcirculation using fundus photography (oct-a) is simple, rapid, non-invasive and inexpensive. it appears to be an interesting alternative to the measurement of imr for the diagnosis of microvascular angina. this hypothesis has never yet been tested. the demonstration of an association between a decrease in retinal vascular density measured by oct-a and an alteration in coronary microvascular function measured by imr would pave the way for a completely non-invasive diagnosis of patients. this is an observational, cohort, prospective, single-center pilot study comparing people who have received an imr measurement as part of inoca. it is planned to include 158 participants. the overall follow-up period for each patient in the research is 12 months. in routine care, imr is measured during coronary angiography in patients presenting with ischemia on a non-invasive test and/or stress symptoms such as angina or dyspnea, for whom coronary angiography does not reveal any significant epicardial lesion. following this examination, two groups will be formed: a group with an imr\<25 and a group with an imr≥25. clinically, the study aims to determine the potential role of retinal oct-a as a non-invasive examination for the diagnosis and/or follow-up of inoca.


Eligibility criteria:
inclusion criteria: * patients managed at dijon university hospital, having had an imr measurement as part of inoca during a coronary angiographic examination, consecutively includible, without angiographically or functionally significant coronary epicardial lesion (ffr \< 0.80) explaining the clinical picture (= inoca) * person having given oral consent * adult exclusion criteria: * person not affiliated or not benefiting from a social security scheme * person subject to a legal protection measure (curatorship, guardianship) or a safeguard of justice measure * pregnant or breast-feeding women * an adult incapable or unable to give consent * person with macular or retinal pathology, or severe bilateral myopia * person with genetic or idiopathic cardiomyopathy (dilated, hypertrophic or restrictive cardiomyopathy)
interprofessional rehabilitation for adults with chronic non-specific low back pain

Conditions: Low Back Pain

Summary: the primary aim of the study is to analyse the long-term effectiveness of an interprofessional and interdisciplinary rehabilitation program named "pastor", with a biopsychosocial approach for participants with chronic non-specific low back pain (clbp) compared to the standard inpatient multidisciplinary orthopaedic rehabilitation (mor) in germany. the investigators hypothesize that in adults with clbp the rehabilitation program pastor would result in a significantly higher increase in functional ability 12 months after completion of the program in comparison to the standard inpatient mor. the investigators further hypothesize that pastor would lead to significantly larger improvements regarding pain-related cognitions, pain coping strategies, physical activity, health-related quality of life, and back pain episodes compared to the standard inpatient mor.


Eligibility criteria:
inclusion criteria: * m51.2 other specified intervertebral disc displacement * m51.3 other specified intervertebral disc degeneration * m51.4 schmorl's nodes * m51.8 other specified intervertebral disc disorders * m51.9 intervertebral disc disorder, unspecified * m53.8 other specified dorsopathies * m53.9 dorsopathy, unspecified * m54.4 lumbago with sciatica * m54.5 low back pain * m54.6 pain in thoracic spine * m54.8 other dorsalgia * m54.9 dorsalgia, unspecified exclusion criteria: * age below 18 years or over 65 years * specific underlying diagnosis of back pain (e. g. radicular symptoms, myelopathy) * considerably reduced health status (e.g. comorbidity) * considerably reduced sight and hearing (not corrected) * severe psychiatric condition as secondary diagnosis * inability to speak german * current application for early retirement or invalidity pension (§51 sg v - german law)

Keywords: rehabilitation treatment outcome interprofessional relations interdisciplinary communication behavioural exercise therapy cognitive therapy health education workplace related information multicenter study
progression from impaired fasting glucose to type 2 diabetes mellitus among subjects with and without hypertension in primary care setting

Conditions: Diabetes Mellitus; Hypertension; Impaired Fasting Glucose

Summary: retrospective cohort of all the patients with elevated blood sugar (but no diabetes) attending the study sites from 2002 to 2007. we retrieval their records to see how many of them actually developed diabetes. the patient's record will be followed up to 6 years after their first abnormally high blood sugar checked. we will measure their parameters including sex, age, pay code and whether they have hypertension or not to see what factors will increase risk of dm development.

we aim at find out the progression of impaired fasting glucose (ifg) to type 2 diabetes mellitus (t2dm) among patients in general practice setting. we can understand the progress of the target patients so as to improve patient education, improve patient motivation in lifestyle modification.we are going to find out the annual incidence of type 2 dm developement among the patients with and without hypertension hypertensive patients with impaired fasting glucose are more likely to develop type 2 diabetes mellitus compare with normal tensive patients

Eligibility criteria:
inclusion criteria:we include all subjects age ≥18 attended the study centers with laboratory diagnosis of ifg by blood sugar 6.1 mmol/l to 6.9 mmol/l checked from 2002 to 2007 in the 6 study centres. - exclusion criteria:we excluded the subjects who have diagnosis of t2dm the years prior to the year of blood taken. we define t2dm by physician coding icpc-2 of t90 diabetes non-insulin dependent or prescription of antidiabetic drugs (british national formulary(23) (bnf) section 6.1 and 6.2). we exclude the patients who had been admitted to hong kong hospital authority (hkha)or attended hkha specialty clinic, or attended any gopc with dispensing history of drug used in diabetes in bnf section 6.1.1 insulins or 6.1.2 anti-diabetic drugs, or with icpc coded with t90) during 1 jan 2005 - 31 dec 2006 (i.e. 2 year prior to starting of study period). we also excluded patient with the date of diagnosis of dm by above criteria earlier than the date of laboratory test results of ifg. -

Keywords: diabetes mellitus hypertension impaired fasting glucose primary health care chinese
the use of lung ultrasonography in covid-19 patients

Conditions: Ultrasonography

Summary: in covid-19 patients hospitalized in the intensive care unit due to respiratory failure, lung ultrasonography will be tried to be given an appropriate position that will effectively use lung capacity and its effect on oxygenation will be investigated.

in this study, the covid-19 patients hospitalized in the intensive care unit due to respiratory failure will be evaluated. participants will be divided into two groups as patients undergoing lung ultrasonography (group ultrasonography ) and those without lung ultrasonography (group control). while performing lung ultrasonography, each hemithorax will be evaluated using anterior axillary line and posterior axillary line into anterior, lateral and posterior region, and each region will be divided into 6 quadrants, upper and lower. each hemithorax will be scanned by the investigators, scored in 6 regions using a convex ultrasonography probe with the lung ultrasound score (lus score). participants in both groups will be evaluated by comparing arterial blood gas analyzes before examination (with/without ultrasonography), at the 2nd and 12th hours. is there any change in arterial blood gas values such as po2 and pco2 at 0, 2 and 12 hours so that oxygenation and ventilation between group ultrasonograpy and group control will be evaluated?

Eligibility criteria:
inclusion criteria: * patients have been diagnosed with covid 19 * patients in the intensive care unit over the age of 18 exclusion criteria: * patients not diagnosed with covid 19 * patients with cardiac problems * patients with renal problems

Keywords: lung ultrasonography intensive care unit position covid-19
impact of sleeve gastrectomy on monocyte-to-high-density lipoprotein cholesterol ratio

Conditions: Laparoscopic Sleeve Gastrectomy; Cardiovascular Risk Factor; Obesity

Summary: the present study hypothesized that significant weight loss is associated with a reduction in the inflammatory markers, leading to diminished cardiovascular risks in patients undergoing laparoscopic sleeve gastrectomy (lgs). we found a decrease in mhr at postoperative 6 months from baseline in patients undergoing lsg. the decrease in mhr was more remarkable with increasing percentage of ewl, but no relationship between the %ewl and mhr.

the present study aims to evaluate the relationship between mhr, metabolic parameters and the percentage of excess weight loss (%ewl) in participants undergoing laparoscopic sleeve gastrectomy (lsg). this prospective cohort study will evaluate obese participants undergoing lsg. demographic data of the participants and blood glucose level, monocyte count and lipid parameters baseline and at 6 months after surgery will record. the mhr baseline and at 6 months after surgery and the %ewl at 6 months after surgery will calculate. the participants will be divide into two groups as participants with %ewl of \<50 and patients with a %ewl of ≥50. the parameters will compare between the two groups.

Eligibility criteria:
inclusion criteria: obese patients (bmi ≥40 or \>35+ and accompanying dm, ht and hyperlipidemia) underwent laparoscopic sleeve gastrectomy. exclusion criteria: receiving antihyperlipidemic therapy, important complications that continue within 6 months after surgery (anastomotic leaks, pulmonary embolism, deep vein thrombosis, soft tissue infection) did not attend 6-month control visit were excluded from the study.
interstitial lung disease questionnaire

Conditions: Interstitial Lung Disease

Summary: 1. to evaluate the health status of patients with interstitial lung disease (ild), and how this varies between subgroups of ild. 2. to investigate the prevalence of symptoms, anxiety, depression, and sleep-disordered breathing within ild patient population. 3. to assess the economic impact of ild. 4. to understand how self-aware ild patients are regarding their treatment/management. 5. to compare the demographic details, including smoking status and occupational history, of patients with interstitial lung disease

primary endpoint • health status in the target populations, as determined by the k-bild questionnaire. secondary endpoints - * severity of dyspnoea suffered by patients * prevalence of anxiety and depression * prevalence of sleep-disordered breathing symptoms * degree of self-awareness displayed by patients * the costs associated with ild from a patient and healthcare perspective. * demographic details

Eligibility criteria:
inclusion criteria: * male or female * age greater than 18 years of age * any smoking status * diagnosis of interstitial lung disease as defined below * full pulmonary lung function tests and routine immunological tests undertaken within 6 months of entry into study exclusion criteria: • unable to give consent to take part

Keywords: ild
towards precision medicine for diabetes in pregnancy

Conditions: Gestational Diabetes; Gestational Diabetes Mellitus

Summary: rationale: gestational diabetes is currently treated by the one-size-fits-all-approach. treatment efficacy is poorly defined and inconsiderate of patients clinical presentation objective: to characterize the efficacy of pharmacological treatment of gestational diabetes mellitus between patients with distinct metabolic phenotypes study design: prospective observational study, in metformin-treatment efficacy is compared between patients with gdm caused by insulin resistance and patients with gdm caused by low insulin secretion. study population: a prospective cohort of 103 women with diagnosed gestational diabetes mellitus treated by metformin. main study parameters/endpoints: primary outcomes is the glucose-disposition-index in late pregnancy (35-37 weeks gestation) and requirement for supplemental insulin-treatment. secondary outcomes include insulin sensitivity (matsuda-index), insulin secretion (stumvoll-index), hba1c, gestational weight gain, body composition, physical activity, eating behavior, plasma biomarkers, glucose control, and maternal and infant pregnancy outcomes.


Eligibility criteria:
inclusion criteria: * having a confirmed single, viable pregnancy past 20 weeks gestation. * assigned to pharmacological (ie metformin) treatment for gdm. exclusion criteria: * pre-existing diabetes, hypertension (sbp \>160 mmhg \& dbp \>110 mmhg) * using medication related to study outcomes prior to gdm diagnosis (insulin, metformin, glyburide, systemic steroids, mood stabilizers, adhd medication) * smoking or using recreational drugs that may affect pregnancy outcomes

Keywords: insulin sensitivity insulin secretion continuous glucose monitoring metformin physical activity